| Bioactivity | Peucedanocoumarin III is an inhibitor of (alpha)-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research[1]. |
| Name | Peucedanocoumarin III |
| CAS | 130464-57-2 |
| Formula | C21H22O7 |
| Molar Mass | 386.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sangwoo Ham, et al. Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates. Mol Cells. 2019 Jun 30;42(6):480-494. |
Peucedanocoumarin III
CAS: 130464-57-2 F: C21H22O7 W: 386.40
Peucedanocoumarin III is an inhibitor of (alpha)-synuclein and Huntington protein aggregates that enhances the clearance
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.